Piceatannol, a selective SYK inhibitor, similar to SYK knockdown, suppressed these malignant phenotypes on SYK-positive CAL27 cells, suggesting the significant role of SYK on oral cancer progression. Here, SYK is linked to lip and oral cavity carcinoma.